NZ549125A - Anti-EpCAM immunoglobulins - Google Patents

Anti-EpCAM immunoglobulins

Info

Publication number
NZ549125A
NZ549125A NZ549125A NZ54912505A NZ549125A NZ 549125 A NZ549125 A NZ 549125A NZ 549125 A NZ549125 A NZ 549125A NZ 54912505 A NZ54912505 A NZ 54912505A NZ 549125 A NZ549125 A NZ 549125A
Authority
NZ
New Zealand
Prior art keywords
cancer
epcam
immunoglobulin
administration
days
Prior art date
Application number
NZ549125A
Other languages
English (en)
Inventor
Malte Peters
Mathias Locher
Nadja Prang
Cornelia Quadt
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of NZ549125A publication Critical patent/NZ549125A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ549125A 2004-02-13 2005-02-09 Anti-EpCAM immunoglobulins NZ549125A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (1)

Publication Number Publication Date
NZ549125A true NZ549125A (en) 2008-09-26

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ549125A NZ549125A (en) 2004-02-13 2005-02-09 Anti-EpCAM immunoglobulins

Country Status (23)

Country Link
US (3) US20050180979A1 (enExample)
EP (2) EP2107071A3 (enExample)
JP (1) JP5220315B2 (enExample)
KR (1) KR101236224B1 (enExample)
CN (1) CN1976951B (enExample)
AT (1) ATE437186T1 (enExample)
AU (1) AU2005215874B2 (enExample)
BR (1) BRPI0507660A (enExample)
CA (1) CA2555694C (enExample)
DE (1) DE602005015544D1 (enExample)
DK (1) DK1713830T3 (enExample)
EA (1) EA011951B1 (enExample)
ES (1) ES2328159T3 (enExample)
IL (1) IL177069A (enExample)
MX (1) MXPA06008942A (enExample)
NO (1) NO339364B1 (enExample)
NZ (1) NZ549125A (enExample)
PL (1) PL1713830T3 (enExample)
PT (1) PT1713830E (enExample)
SI (1) SI1713830T1 (enExample)
UA (1) UA87128C2 (enExample)
WO (1) WO2005080428A2 (enExample)
ZA (1) ZA200606083B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5686493B2 (ja) 2003-01-24 2015-03-18 ユニバーシティ・オブ・ユタＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｕｔａｈ テロメアの長さを決定することによって死亡の危険性を予測する方法
EP2004695A2 (en) 2005-07-08 2008-12-24 Xencor, Inc. Optimized anti-ep-cam antibodies
US7976842B2 (en) * 2006-02-09 2011-07-12 Micromet Ag Treatment of metastatic breast cancer
EP2041181B1 (en) * 2006-06-08 2011-05-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Specific protease inhibitors and their use in cancer therapy
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
ES2367675T3 (es) * 2007-04-04 2011-11-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anticuerpo anti-epcam y usos del mismo.
JP5840950B2 (ja) 2008-12-22 2016-01-06 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 単色マルチプレックス定量ｐｃｒ
JP6048660B2 (ja) * 2009-09-21 2016-12-21 ランジュ ラルハン 甲状腺癌を診断および処置するための方法および組成物
CN104168916B (zh) * 2012-03-02 2017-07-04 中央研究院 抗上皮细胞黏着分子(EpCAM)抗体及其使用方法
CN103387988B (zh) * 2012-09-24 2016-01-06 厦门大学 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法
CN105283559A (zh) 2013-05-22 2016-01-27 端粒诊断公司 短端粒丰度的量度
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
AU2015204766B2 (en) * 2014-01-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
AU2015372584A1 (en) 2014-12-30 2017-06-29 Telomere Diagnostics, Inc. Multiplex quantitative PCR
EP3903818A1 (en) * 2015-11-19 2021-11-03 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
AU2017301826A1 (en) 2016-07-26 2019-03-14 Tessa Therapeutics Ltd. Chimeric antigen receptor
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
TR199902553T2 (xx) * 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
KR100900166B1 (ko) * 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
EP1575491A4 (en) * 2002-05-20 2006-09-27 Abgenix Inc TREATMENT OF RENAL CARCINOMA USING ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR

Also Published As

Publication number Publication date
AU2005215874B2 (en) 2011-01-27
PT1713830E (pt) 2009-10-19
AU2005215874A1 (en) 2005-09-01
IL177069A (en) 2010-11-30
KR101236224B1 (ko) 2013-02-22
DE602005015544D1 (de) 2009-09-03
ES2328159T3 (es) 2009-11-10
HK1096103A1 (en) 2007-05-25
US20050180979A1 (en) 2005-08-18
EP2107071A3 (en) 2009-12-30
CA2555694C (en) 2013-04-16
UA87128C2 (ru) 2009-06-25
EA200601386A1 (ru) 2007-06-29
WO2005080428A2 (en) 2005-09-01
EP1713830B1 (en) 2009-07-22
PL1713830T3 (pl) 2010-01-29
WO2005080428A3 (en) 2005-11-10
SI1713830T1 (sl) 2009-10-31
EP2107071A2 (en) 2009-10-07
CN1976951A (zh) 2007-06-06
JP2008500277A (ja) 2008-01-10
CA2555694A1 (en) 2005-09-01
EP1713830A2 (en) 2006-10-25
IL177069A0 (en) 2006-12-10
ATE437186T1 (de) 2009-08-15
BRPI0507660A (pt) 2007-07-17
EA011951B1 (ru) 2009-06-30
US20120294873A1 (en) 2012-11-22
DK1713830T3 (da) 2009-10-12
ZA200606083B (en) 2007-10-31
US20070274982A1 (en) 2007-11-29
MXPA06008942A (es) 2007-01-26
KR20070009988A (ko) 2007-01-19
NO339364B1 (no) 2016-12-05
NO20064136L (no) 2006-11-07
CN1976951B (zh) 2012-03-14
JP5220315B2 (ja) 2013-06-26

Similar Documents

Publication Publication Date Title
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
EP3334431B1 (en) 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
US8841424B2 (en) Humanized AXL antibodies
JP2021193096A (ja) Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
KR20190136076A (ko) 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
WO1994022478A1 (en) PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
US6733752B1 (en) Prevention of tumors with monoclonal antibodies against neu
CN114044827B (zh) 低adcc/cdc功能性单抗及其制备方法与应用
CN112739716A (zh) 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
EP2270053A1 (en) Humanized AXL antibodies
JP2023554422A (ja) がんの治療のための多重特異性抗体
CN112996540A (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
CN112672759B (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
HK1096103B (en) Anti-epcam immunoglobulins
WO2023227115A1 (en) A method of treating solid tumor
CN114685674B (zh) 一种抗体融合蛋白及其应用
EP4470562A1 (en) Anti-pd-l1 antibody-containing pharmaceutical composition used in combination with anti-vegf antibodies and paclitaxel
KR20240038204A (ko) Pd-1에 특이적으로 결합하는 항체를 유효성분으로 포함하는 신경내분비 신생물의 예방 또는 치료용 약학 조성물
WO2026052074A1 (zh) 包含抗体偶联药物和免疫检查点抑制剂的药物组合及其应用
Garrett Peptide-based B-cell epitope vaccines targeting HER-2/neu
HK1249409B (en) 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
HK1249409A1 (en) 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2016 BY CPA GLOBAL

Effective date: 20141230

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2017 BY CPA GLOBAL

Effective date: 20151231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2018 BY CPA GLOBAL

Effective date: 20161230

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2019 BY CPA GLOBAL

Effective date: 20180104

LAPS Patent lapsed